NCEL Overview

NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.

Wall Street analysts forecast NCEL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NCEL is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

NewcelX AG revenue for the last quarter amounts to NaN USD, decreased

NewcelX AG. EPS for the last quarter amounts to USD, decreased

NewcelX AG (NCEL) has 9 emplpoyees as of June 10 2026.

Today NCEL has the market capitalization of 17.44M USD.